Clinical Trial Update: Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating vericiguat versus placebo to improve physical function in Post-COVID-19 syndrome; the study is active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myalgic Encephalomyelitis Chronic Fatigue Syndrome
• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Vericiguat (vericiguat)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Post-COVID ME/CFS | Phase 2 | Status: ACTIVE_NOT_RECRUITING